½ÃÀ庸°í¼­
»óǰÄÚµå
1550765

¼¼°è ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå : Á¦Çüº°, ¿ëµµº°, Áö¿ªº°

Cyproterone Acetate Market, By Formulation, By Application, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå ±Ô¸ð´Â 2024³â 3¾ï 2,710¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024-2031³âÀÇ CAGRÀº 4.5%¸¦ ³ªÅ¸³»¸ç, 2031³â¿¡´Â 4¾ï 4,510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÈ´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2023³â 2024³â ½ÃÀå ±Ô¸ð 3¾ï 2,710¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø±â°£ 2024-2031³â CAGR: 4.50% 2031³â °¡Ä¡ ¿¹Ãø 4¾ï 4,510¸¸ ´Þ·¯
±×¸² : ½ÃÇÁ·Î Å×·Ð ¾Æ¼¼Å×ÀÌÆ®ÀÇ Áö¿ªº° ½ÃÀå Á¡À¯À²(%), 2024
Cyproterone Acetate Market-IMG1

½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ®(CPA)´Â Ȳü È£¸£¸ó°ú Ç× ¾Èµå·Î°Õ ½ºÅ×·ÎÀÌµå ¾à¹°·Î ÁÖ·Î Àü¸³¼± ¾Ï, »çÃá±â Á¶±â ¹ßº´, ¿©µå¸§ ¹× ¿©¼ºÀÇ °úµµÇÑ ¹ß¸ð¸¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. Ȳü È£¸£¸ó ÀÛ¿ëÁ¦ ¶Ç´Â ±æÇ×Á¦·Î ÀÛ¿ëÇÏ°í ¾Èµå·Î°Õ ¼ö¿ëü¿Í °æÀïÇÏ¿© Ç× ¾Èµå·Î°ÕÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. CPA´Â ÀÓ»óÀûÀ¸·Î °¡Àå »¡¸® »ç¿ëµÇ´Â Ç× ¾Èµå·Î°Õ Áß ÇϳªÀ̸ç ÇöÀçµµ ÀÓ»ó ÀûÀ¸·Î »ç¿ëµÇ´Â Áß¿äÇÑ ¾à¹°ÀÔ´Ï´Ù. ´Üµ¶À¸·Îµµ, ¿¡½ºÆ®·Î°Õ°úÀÇ º´¿ëÀ¸·Îµµ, ¼¼°è¿¡¼­ ´Ù¾çÇÑ ºê·£µå¸íÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀåÀº ³²¼º¿¡¼­ Àü¸³¼±¾ÏÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÏ°í ¿©¼º¿¡¼­ ¿©µå¸§°ú ´Ù¸ðÁõÀÇ Áõ·Ê°¡ Áõ°¡ÇÔ¿¡ µû¶ó °ßÀεǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È­¿Í ³ëÀÎ Àα¸ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀ̵Ǿú½À´Ï´Ù. ±×·¯³ª °£µ¶¼º, ÇÇ·Î, ¿ì¿ïÁõ°ú °°Àº ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ®ÀÇ Àå±â°£ »ç¿ë°ú °ü·ÃµÈ ºÎÀÛ¿ëÀº ´ëü ¾à¹°ÀÇ °¡¿ë¼º°ú ÇÔ²² ½ÃÀå È®´ë¸¦ ¾î´À Á¤µµ ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±ÇÑ °ø¾×Çü CPAÀÇ °³¹ßÀº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2023³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µî°ú °°Àº ¸Å°³º¯¼ö¸¦ ¹ÙÅÁÀ¸·Î ¼¼°è ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀº ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.
  • ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå : Á¦Á¦º°(2024-2031³â)

  • Á¤Á¦
  • ÁÖ»çÁ¦
  • ±¹¼Ò¿ë Á¦Á¦

Á¦5Àå ¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå : ¿ëµµº°(2024-2031³â)

  • È£¸£¸ó º¸Ãæ ¿ä¹ý
  • ÇÇÀÓ
  • ¿©µå¸§ Ä¡·á
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ½ÃÇÁ·ÎÅ×·Ð ¾Æ¼¼Å×ÀÌÆ® ½ÃÀå :Áö¿ªº°(2019-2031³â)

  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«

Á¦7Àå °æÀï ±¸µµ

  • Curia
  • Axplora
  • LGM Pharma
  • Hubei Gedian Humanwell Pharmaceutical
  • Cipla
  • NEWCHEM SPA
  • Swati Spentose
  • Teva API
  • Teva Pharmaceutical Industries
  • Unipex
  • Zhejiang Xianju Pharmaceutical Co. Ltd
  • KRKA
  • Cambrex
  • Sicor De Mexico
  • Zhejiang Xianju Xianle
  • Shaoxing Hantai Pharma
  • Farmabios

Á¦8Àå ºÐ¼®°¡ Ãßõ

  • Wheel of Fortune
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map(COM)

Á¦9Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
JHS 24.10.02

The global cyproterone acetate market is estimated to be valued at USD 327.1 Mn in 2024 and is expected to reach USD 445.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 327.1 Mn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 4.50% 2031 Value Projection: US$ 445.1 Mn
Figure. Cyproterone Acetate Market Share (%), By Region 2024
Cyproterone Acetate Market - IMG1

Cyproterone acetate (CPA) is a progestogen and antiandrogen steroid medication that is used primarily in the treatment of prostate cancer, precocious puberty, acne, and excessive hair growth in women. It acts as a progesterone agonist or antagonist and as an antiandrogen by competing for the androgen receptor. CPA was one of the earliest clinically used antiandrogens and remains an important medication in clinical use today. It is available both as a standalone medication and in combination with an estrogen under various brand names throughout the world.

Market Dynamics:

The global cyproterone acetate market is driven by the increasing incidence of prostate cancer in men, and rising cases of acne and hirsutism in women. Moreover, shifting lifestyle patterns and growing geriatric population are major factors fueling the market growth. However, side effects associated with the long-term use of cyproterone acetate such as liver toxicity, fatigue, and depression along with the availability of alternative medications are expected to hamper market expansion to some extent. The development of conjugated forms of CPA with improved safety profiles can create lucrative opportunities over the forecast period.

Key Features of the Study:

  • This report provides in-depth analysis of the global cyproterone acetate market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cyproterone acetate market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Curia, Axplora, LGM Pharma, Hubei Gedian Humanwell Pharmaceutical, Cipla, NEWCHEM SPA, Swati Spentose, Teva API, Teva Pharmaceutical Industries, Unipex, Zhejiang Xianju Pharmaceutical Co. Ltd, KRKA, Cambrex, Sicor De Mexico, Zhejiang Xianju Xianle, Shaoxing Hantai Pharma, and Farmabios
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global cyproterone acetate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cyproterone acetate market

Detailed Segmentation:

  • Formulation Insights (Revenue, USD Mn, 2019 - 2031)
    • Tablets
    • Injectables
    • Topical Preparations
  • Application Insights (Revenue, USD Mn, 2019 - 2031)
    • Hormonal Replacement Therapy
    • Contraception
    • Acne Treatment
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Curia
    • Axplora
    • LGM Pharma
    • Hubei Gedian Humanwell Pharmaceutical
    • Cipla
    • NEWCHEM SPA
    • Swati Spentose
    • Teva API
    • Teva Pharmaceutical Industries
    • Unipex
    • Zhejiang Xianju Pharmaceutical Co. Ltd
    • KRKA
    • Cambrex
    • Sicor De Mexico
    • Zhejiang Xianju Xianle
    • Shaoxing Hantai Pharma
    • Farmabios

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

  • Research Objectives
  • Assumptions
  • Abbreviations

2. MARKET PURVIEW

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Cyproterone Acetate Market, By Formulation
    • Global Cyproterone Acetate Market, By Application

3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Cyproterone Acetate Market, By Formulation, 2024-2031, (USD Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Tablets
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Injectables
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Topical Preparations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Cyproterone Acetate Market, By Application, 2024-2031, (USD Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hormonal Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Contraception
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Acne Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Cyproterone Acetate Market, By Region, 2019 - 2031, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
    • Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
  • South Africa
  • North Africa
  • Central Africa

7. COMPETITIVE LANDSCAPE

  • Curia
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Axplora
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • LGM Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hubei Gedian Humanwell Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NEWCHEM SPA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Swati Spentose
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva API
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Unipex
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zhejiang Xianju Pharmaceutical Co. Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • KRKA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cambrex
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sicor De Mexico
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zhejiang Xianju Xianle
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shaoxing Hantai Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Farmabios
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

9. References and Research Methodology

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦